MCRPF logo

MicroPort Scientific Corporation (MCRPF) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $, MicroPort Scientific Corporation (MCRPF) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 59/100, una calificación moderada basada en 9 KPI cuantitativos.

Ultimo analisis: 17 mar 2026
Puntuación de IA de 59/100

MicroPort Scientific Corporation (MCRPF) Resumen de Asistencia Médica y Tuberías

CEOZhaohua Chang
Empleados6347
Sede CentralShanghai, CN
Año de la oferta pública inicial (OPI)2012

MicroPort Scientific Corporation is a global medical device company specializing in cardiovascular, orthopedic, and surgical robotic solutions. With a focus on innovation and international expansion, MicroPort serves diverse markets, including China, North America, and Europe, positioning itself as a key player in the medical device industry.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 17 mar 2026

Tesis de Inversión

MicroPort Scientific Corporation presents a mixed investment thesis. The company's diverse product portfolio across multiple high-growth medical device segments, including surgical robotics and cardiovascular devices, offers significant growth potential. Expansion into international markets, particularly in emerging economies, could drive revenue growth. However, the company's negative profit margin of -16.1% and negative P/E ratio of -12.91 raise concerns about profitability. Successful commercialization of its surgical robot technologies and continued innovation in its core cardiovascular and orthopedic segments are key to future success. Investors should closely monitor the company's ability to improve profitability and manage its operating expenses.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market Cap of $2.90B reflects its position as a significant player in the medical device market.
  • Gross Margin of 54.1% indicates strong pricing power and efficient manufacturing processes.
  • Operating in multiple segments including Cardiovascular Devices, Orthopedics Devices, and Surgical Robot Business, diversifying its revenue streams.
  • Global presence in the People's Republic of China, North America, Europe, other Asian countries, and South America.
  • Beta of 0.39 suggests lower volatility compared to the overall market.

Competidores y Pares

Fortalezas

  • Diverse product portfolio across multiple medical device segments.
  • Strong presence in China and other emerging markets.
  • Innovative surgical robotics platform.
  • Established brand reputation and relationships with healthcare providers.

Debilidades

  • Negative profit margin and P/E ratio.
  • High operating expenses.
  • Dependence on regulatory approvals for new products.
  • Exposure to currency fluctuations.

Catalizadores

  • Upcoming: Regulatory approvals for new medical devices in key markets.
  • Upcoming: Commercialization of surgical robots in China and other emerging markets.
  • Ongoing: Expansion of distribution network and partnerships with healthcare providers.
  • Ongoing: Continued innovation in cardiovascular and orthopedic devices.
  • Ongoing: Strategic acquisitions to expand product portfolio and geographic reach.

Riesgos

  • Potential: Intense competition from established medical device companies.
  • Potential: Stringent regulatory requirements and product recalls.
  • Potential: Pricing pressures from healthcare providers and payers.
  • Ongoing: Negative profit margin and high operating expenses.
  • Ongoing: Dependence on regulatory approvals for new products.

Oportunidades de crecimiento

  • Expansion of Surgical Robotics Business: MicroPort's Surgical Robot Business segment represents a significant growth opportunity. The global surgical robotics market is projected to reach $14.4 billion by 2026, growing at a CAGR of 12.7%. Successful commercialization of its surgical robots, particularly in China and other emerging markets, could drive substantial revenue growth. The company's focus on developing cost-effective and versatile robotic platforms could provide a competitive advantage.
  • Penetration of Emerging Markets: Expanding its presence in emerging markets, particularly in Asia and South America, offers significant growth potential. These markets are experiencing rapid growth in healthcare expenditure and increasing demand for advanced medical devices. MicroPort's established presence in China provides a strong foundation for expanding into other Asian markets. Tailoring its products and services to meet the specific needs of these markets could drive revenue growth.
  • Innovation in Cardiovascular Devices: Continued innovation in its Cardiovascular Devices segment, including the development of next-generation stents and delivery systems, is crucial for maintaining its competitive position. The global cardiovascular devices market is projected to reach $60 billion by 2026. Focusing on developing innovative solutions for complex coronary artery diseases and expanding its product portfolio to include new therapeutic areas could drive growth.
  • Growth in Orthopedic Devices: The Orthopedics Devices segment offers growth opportunities through the development of advanced implants and surgical techniques. The global orthopedic devices market is projected to reach $55 billion by 2026. Focusing on developing personalized implants and minimally invasive surgical solutions could drive growth in this segment. Expanding its distribution network and strengthening its relationships with orthopedic surgeons are also important for success.
  • Strategic Acquisitions and Partnerships: Pursuing strategic acquisitions and partnerships to expand its product portfolio and geographic reach represents another growth opportunity. Acquiring companies with complementary technologies or established market positions could accelerate its growth and enhance its competitive advantage. Partnering with leading research institutions and healthcare providers could also drive innovation and improve its market access.

Oportunidades

  • Expansion of surgical robotics business.
  • Penetration of emerging markets.
  • Innovation in cardiovascular and orthopedic devices.
  • Strategic acquisitions and partnerships.

Amenazas

  • Intense competition from established medical device companies.
  • Stringent regulatory requirements and product recalls.
  • Pricing pressures from healthcare providers and payers.
  • Economic slowdown in key markets.

Ventajas competitivas

  • Strong brand reputation in the medical device industry.
  • Extensive product portfolio across multiple therapeutic areas.
  • Established presence in China and other emerging markets.
  • Proprietary technologies and intellectual property.
  • Strong relationships with key opinion leaders and healthcare providers.

Acerca de MCRPF

Founded in 1998 and headquartered in Shanghai, China, MicroPort Scientific Corporation has evolved into a prominent global medical device company. The company's initial focus was on developing and manufacturing cardiovascular devices, specifically coronary stents, to address the growing need for advanced cardiac care in China. Over the years, MicroPort expanded its product portfolio through strategic acquisitions and internal research and development, venturing into orthopedics, cardiac rhythm management, endovascular solutions, neurovascular devices, heart valve technologies, surgical robots, and surgical devices. Today, MicroPort operates through several key segments. The Cardiovascular Devices segment offers coronary stents and related delivery systems. The Orthopedics Devices segment provides reconstructive joints and spine implants. The Cardiac Rhythm Management Business segment offers defibrillators and pacemakers. The Endovascular and Peripheral Vascular Devices segment provides products for aortic and peripheral vascular diseases. The Neurovascular Devices segment offers neurovascular therapeutic devices. The Heart Valve Business segment provides transcatheter aortic valves. The Surgical Robot Business segment designs surgical robots. The Surgical Devices segment researches and sells surgical devices. MicroPort distributes its products across China, North America, Europe, and other international markets.

Qué hacen

  • Manufactures and distributes medical devices globally.
  • Offers products for cardiovascular diseases, including coronary stents and delivery systems.
  • Provides orthopedic implants for reconstructive joint surgery and spine procedures.
  • Develops and markets cardiac rhythm management devices, such as defibrillators and pacemakers.
  • Offers endovascular and peripheral vascular devices for treating aortic and vascular diseases.
  • Provides neurovascular devices for treating neurovascular diseases.
  • Develops and commercializes surgical robots for various surgical procedures.
  • Manufactures and sells surgical devices.

Modelo de Negocio

  • Develops, manufactures, and markets a broad range of medical devices.
  • Generates revenue through the sale of its products to hospitals, clinics, and healthcare providers.
  • Invests in research and development to innovate and expand its product portfolio.
  • Distributes its products through a network of sales representatives and distributors.
  • Focuses on international expansion to drive revenue growth.

Contexto de la Industria

The medical device industry is characterized by continuous innovation, stringent regulatory requirements, and increasing demand driven by an aging global population and rising healthcare expenditure. MicroPort Scientific Corporation operates in a competitive landscape that includes major players like Medtronic, Johnson & Johnson, and Stryker, as well as specialized competitors in each of its segments. The industry is experiencing growth in minimally invasive surgery, robotic surgery, and personalized medicine, creating opportunities for MicroPort to leverage its R&D capabilities and expand its market share. The global medical devices market is projected to reach $600 billion by 2026, with a CAGR of 5.4%.

Clientes Clave

  • Hospitals and clinics
  • Healthcare providers
  • Surgeons and interventional cardiologists
  • Patients requiring medical device implants and therapies
  • Distributors and sales representatives
Confianza de la IA: 71% Actualizado: 17 mar 2026

Finanzas

Gráfico e información

Precio de la acción de MicroPort Scientific Corporation (MCRPF): Price data unavailable

Últimas noticias

No hay noticias recientes disponibles para MCRPF.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para MCRPF.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para MCRPF.

MoonshotScore

59/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de MCRPF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Zhaohua Chang

CEO

Zhaohua Chang is the Chief Executive Officer of MicroPort Scientific Corporation. His background includes extensive experience in the medical device industry, with a focus on strategic planning, business development, and operational management. He has been instrumental in driving the company's growth and expansion into new markets. His leadership is focused on innovation and globalization.

Historial: Under Zhaohua Chang's leadership, MicroPort Scientific Corporation has expanded its product portfolio and strengthened its presence in key markets. He has overseen the development and commercialization of innovative medical devices, including surgical robots and advanced cardiovascular solutions. He is managing 6347 employees.

Información del mercado OTC de MCRPF

The OTC Other tier represents the lowest tier of the OTC market, indicating that MicroPort Scientific Corporation may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous listing standards and regulatory oversight.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity in OTC Other stocks can be highly variable and often limited. Bid-ask spreads may be wide, and trading volume can be thin, making it difficult to buy or sell shares quickly and at desired prices. Investors may experience significant price fluctuations due to the lack of market depth. Assessing the average daily trading volume and bid-ask spread is crucial before investing.
Factores de riesgo OTC:
  • Limited financial disclosure increases information asymmetry and the risk of fraud.
  • Lower liquidity can lead to difficulty in buying or selling shares.
  • Wider bid-ask spreads can result in higher transaction costs.
  • Less regulatory oversight increases the risk of mismanagement and corporate governance issues.
  • Higher price volatility can lead to significant losses.
Lista de verificación de diligencia debida:
  • Verify the company's registration and legal status.
  • Review available financial statements and disclosures.
  • Assess the company's management team and their track record.
  • Evaluate the company's business model and competitive landscape.
  • Check for any regulatory actions or legal disputes.
  • Monitor trading volume and bid-ask spreads.
  • Consult with a financial advisor.
Señales de legitimidad:
  • Established presence in the medical device industry.
  • Global operations and distribution network.
  • Diverse product portfolio across multiple therapeutic areas.
  • Focus on innovation and research and development.
  • Experienced management team.

Preguntas Comunes Sobre MCRPF

¿Cuáles son los factores clave para evaluar MCRPF?

MicroPort Scientific Corporation (MCRPF) actualmente tiene una puntuación IA de 59/100, indicando puntuación moderada. Fortaleza clave: Diverse product portfolio across multiple medical device segments.. Riesgo principal a monitorear: Potential: Intense competition from established medical device companies.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de MCRPF?

MCRPF actualmente puntúa 59/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de MCRPF?

Los precios de MCRPF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre MCRPF?

La cobertura de analistas para MCRPF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en MCRPF?

Las categorías de riesgo para MCRPF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition from established medical device companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de MCRPF?

La relación P/E para MCRPF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está MCRPF sobrevalorada o infravalorada?

Determinar si MicroPort Scientific Corporation (MCRPF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de MCRPF?

MicroPort Scientific Corporation (MCRPF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Limited analyst coverage due to OTC listing.
  • Financial data based on available public information.
Fuentes de datos

Popular Stocks